Kodak’s Q2 Earnings: No Analysts, No Guidance

Forward-Looking Analysis

Eastman Kodak (KODK) faces significant uncertainty for its Q2 2026 earnings report scheduled for August 4, 2026. Currently, no Wall Street analysts have provided consensus EPS or revenue forecasts, resulting in "Not Available" status for price targets and earnings estimates. This lack of analyst coverage highlights the difficulty in projecting near-term financial performance for the company. Historical data indicates a continued downward trend in profitability, with Q1 2026 reporting an EPS of -$0.21 and Q4 2025 showing a substantial loss of -$1.12. The absence of analyst guidance suggests market skepticism regarding immediate turnaround metrics. While the company completed a major pension reversion in late 2025, injecting over $1 billion into its balance sheet, the operational core remains challenged. Investors must rely on internal company updates rather than external projections, as no bank predictions or upgrades are currently available for the upcoming quarter.

Historical Performance Review

Eastman Kodak’s Q1 2026 results reflected ongoing operational struggles, with consolidated revenue holding at $265 million. However, profitability deteriorated significantly, posting a GAAP net loss of $16 million compared to prior periods. The company reported an EPS of -$0.21, a sharp decline from the -$0.12 loss in Q1 2025, though still an improvement from the -$0.36 loss seen in Q2 2025. Gross profit stood at $57 million, indicating persistent margin pressures despite stable top-line figures. These metrics underscore the company's continued difficulty in achieving sustainable profitability amidst its strategic transition.

Additional News

Kodak has actively expanded its Advanced Materials and Chemicals (AM&C) portfolio, recently adding four regulated pharmaceutical products, including PBS 1X and Water for Injection, to its cGMP-compliant facility in Rochester. This move supports the company's shift toward high-value regulated markets. Strategically, Kodak partnered with Ateios Systems to demonstrate its RaiCure™ platform for high-speed, solvent-free lithium-ion battery electrode production, achieving speeds of 80 meters per minute. This technology promises a 96% reduction in energy consumption and targets the $196 billion global battery market. Additionally, Kodak completed its pension reversion process in December 2025, receiving $1.023 billion in excess assets. The company utilized $312 million to prepay term loans, reducing debt, while fully funding a new defined benefit plan. Brand partnerships also continue, with Kodak sponsoring the USA Bobsled/Skeleton team, leveraging its heritage to maintain visibility in competitive sports.

Summary & Outlook

Kodak’s financial health shows mixed signals: strong balance sheet improvements from pension reversion versus persistent operational losses. The AM&C segment offers growth catalysts through pharmaceutical and battery technologies, yet the core print business remains under pressure. With no analyst coverage and a history of missed expectations, the near-term outlook remains neutral to bearish. While debt reduction enhances liquidity, sustainable profitability is not yet achieved. Investors should monitor AM&C revenue growth closely as the primary driver for potential valuation recovery, though significant execution risks persist in scaling new manufacturing capabilities.